- Home
- BNRG vs GCTK Comparison
BNRG vs GCTK Comparison
Compare BNRG & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNRG | GCTK |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | BNRG | GCTK |
|---|---|---|
| Price | $1.83 | $1.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 146.5K | ★ 939.2K |
| Earning Date | 02-27-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $387,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 843.90 | N/A |
| 52 Week Low | $2.19 | $1.52 |
| 52 Week High | $60.55 | $40.78 |
Technical Indicators
Market Signals| Indicator | BNRG | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 24.91 |
| Support Level | $2.19 | $1.52 |
| Resistance Level | $2.84 | $1.89 |
| Average True Range (ATR) | 0.46 | 0.30 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 35.97 | 10.96 |
Price Performance
Historical ComparisonAbout BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.